]>
IRCT20150817023666N9 IRCT 2018-01-30 Iran University of Medical Sciences The effects of cabergoline in reducing the size of endometrioma The effects of cabergoline in reducing the size of endometrioma endometriosis 2018-01-21 anticipated 32 Complete https://irct.ir/trial/29002 interventional Randomization: Randomized, Blinding: Triple blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: for randomization, we are using block randomization which patient put in Foursquare blocks, Blinding description: This study is three-blind, so that a researcher, a patient, and a statistical analyst are unaware of the allocation of the two groups to the study.Since the administration of the drug is in combination with other drugs, the subject is not aware of the status of allocation to the groups. A researcher measuring clinical and diagnostic measures will not be aware of the status of the individual, and the statistician will be unaware of the allocation of people to study groups. Only the observer will be aware of the allocation of the groups. 3 Endometriosis of ovary. Intervention 1: Intervention group: Patients receiving cabergoline. Intervention 2: Control group: Placebo recipient. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is No more information
public Abolfazl Mehdizadeh-Kashi
Rasoul-e-Akram Hospital, Mazar-i-Mansouri St., Sattarkhan Street
Tehran Iran (Islamic Republic of) 1445613131 +98 66509283 s.rokhgireh@gmail.com Iran University of Medical Sciences scientific Samaneh Rokhgireh
Rasoul-e-Akram Hospital, Mazar-i-Mansouri St., Sattarkhan Street
Tehran Iran (Islamic Republic of) 1445613131 +98 21 6650 9283 s.rokhgireh@gmail.com Iran University of Medical Sciences Iran (Islamic Republic of) one-sided endometrioma Size less than 5 cm No ultrasound criteria for malignancy The absence of laboratory criteria for malignancy Have informed consent to enter the study Maximum 45 years no limit 45 years Female Hormonal treatment includes Contraceptive 3 months before entering the study Cabergolin sensitivity N80.1 Endometriosis of ovary Treatment - Drugs Placebo Intervention group: Patients receiving cabergoline Control group: Placebo recipient Primary outcome: 25% reduction in endometrium size. Timepoint: Treatment is done for 12 weeks for intervention and control groups. Method of measurement: The results of ultrasound. Iran University of Medical Sciences Approved 2018-01-20 Ethics committee of Iran University of Medical Sciences Rasoul-e-Akram Hospital, Mazar-i-Mansouri St., Sattarkhan Street tehran Tehran Iran (Islamic Republic of)